

COMPARISON OF THE DURATION OF EFFECT OF TWO HYALURONIC ACIDS IN KNEE OSTEOARTHRITIS



M.H. García Lagunar, I. Muñoz García, M.C. Mira Sirvent, A.C. Viney, A. García Márquez, M.C. González Pérez-Crespo, B. Fernández Lobato, L. Escondrillas Gómez, A.M. Chica Marchal, M. Martínez Penella
 Santa Lucía General University Hospital, Department of Hospital Pharmacy, Cartagena, Spain.

Background

Viscosupplementation consists of intra-articular infiltration of hyaluronic acid (HA) to improve viscosity, reduce inflammation and relieve pain in patients with knee osteoarthritis.

Purpose

To compare the percentage of patients who have required more than one dose of sodium hyaluronate (AdantOne®) versus more than one dose of hylan G-F-20 (SynviscOne®) in the same knee in less than a year.

Material and methods

Retrospective observational study including all patients with knee osteoarthritis who were treated with HA between February 2013 and October 2016.

This period was divided into 2 stages

- First stage:** February 2013 – January 2015 (24 months) the HA available was **AdantOne®**
- Second stage:** February 2015 – October 2016 (21 months) the HA available was **SynviscOne®**


Variables analyzed were: number of patients, dispensed units, date of infiltration, medical service

from the Hospital Pharmacy software program (Savac®) and the medical records program (Selene®)


Results

First stage

AdantOne® was dispensed to **944 patients**




72 patients (7.63%) required ≥ 2 doses of HA in the same knee in less than a year




Second stage

SynviscOne® was dispensed to **1193 patients**



91 patients (7.63%) required ≥ 2 doses of HA in the same knee in less than a year



Conclusion

➔ The percentage of patients who have required more than one dose was the same with the two presentations of HA. However, the second stage was shorter than the first suggesting that the duration of the effect of SynviscOne® is less than the duration of AdantOne®.

➔ Our results show that the percentage of patients that have required two or more doses of HA in the same knee in a time period of less than one year is not very high.

➔ These results along with the price are important in the selection of HA.



22nd Congress of EAHP



CP-069